SAHARA+ Conference 2026 — Evidence to Impact: Driving Saudi Healthcare Transformation
9–10 October 2026 · Crowne Plaza RDC, Riyadh, Saudi Arabia · In-Person
The 3rd Annual SAHARA+ Conference — Saudi Arabia's Healthcare Advancement for Resourceful Funding, Regulatory Excellence, And Innovation — is a strategic platform dedicated to sustainable healthcare transformation in the Kingdom, reflecting Saudi Arabia's shift toward a value-based, patient-centred, innovation-driven and financially sustainable health system aligned with Vision 2030.
SAHARA+ brings together healthcare policymakers, regulators, HTA experts, payers, providers and industry leaders to translate evidence into real-world impact. The programme focuses on Health Technology Assessment, evidence-based decision-making, regulatory excellence, value-based healthcare and sustainable financing models, alongside market access, digital health and healthcare innovation. A strong emphasis is placed on specialty pharmaceuticals evaluation, clinical trends, resource utilisation management, pharmacoeconomics and real-world evidence.
Key focus areas
- Healthcare transformation and system sustainability
- Health Technology Assessment (HTA) and evidence-based decision making
- Specialty pharmaceuticals evaluation and clinical value optimisation
- Sustainable funding, value-based healthcare and resource utilisation management
- Regulatory excellence, market access and policy innovation
- Innovation, digital health and data-driven healthcare
- Patient outcomes, population health and therapeutic area focus — oncology, rare disease and other high-burden conditions
Steering committee
Chaired by Prof. Ahmed Al Jedai, Founding President of the Saudi Society of Clinical Pharmacy and Professor at Alfaisal University, with Mohammed Alshennawi (General Director, General Administration of Pharmaceutical Care, Ministry of Health) as Vice Chair, Wejdan Aburas (Center for National Health Insurance) as Organizing Committee Chair and Hajer Al-Mudaiheem (Saudi Society of Clinical Pharmacy) as Scientific Committee Chair.
Faculty highlights
More than 30 confirmed speakers include Yazed AlRuthia (Saudi Society of Pharmacoeconomics & Outcomes Research), Ahmed Alfares (Genomic Medicine Center of Excellence, KFSHRC), Majid Almadi (President, Saudi Gastroenterology Association), Hisham Badreldin (Saudi Biobank Center, KAIMRC), Nawaf Albali (Council of Health Insurance), Manar Samman (Ministry of Health laboratory operations), Abeer Al Rabayah (King Hussein Cancer Center, Jordan) and Zuhair Alhassnan (National Committee for Genetic Diseases).
Who should attend
Regulatory authorities, pharmacists, health economists, hospital executives and administrators, clinicians and key opinion leaders, HTA specialists, payers and insurance drug pricing and reimbursement teams, RWE/RWD experts, HEOR professionals, digital health innovators and pharmaceutical market access teams.
Registration
Early-bird and standard rates apply (standard rate 500 SAR; prices subject to 15% VAT). Registration is handled through the organiser's official booking page.
